Glaucoma is a disease in which damage to the optic nerve leads to the progressive, irreversible death of retinal cells and vision loss. Glaucoma is the second leading cause of blindness. The Glaucoma research group aims to fast track the translation of discoveries from the University of Birmingham research laboratories to improve outcomes for all patients with this debilitating degenerative condition.
Our ophthalmologists, psychiatrists, psychologists, neurologists, neuroscientists and bioengineers work together to develop a multi-disciplinary approach to research into glaucoma. We are pioneering advances in our understanding of the cellular and molecular events that underlie the disease to deliver excellence in innovation for the treatment of this complex disease to deliver excellence in innovation for the treatment of this complex disease.
Of special interest to the group is research that advances our understanding of the mechanisms responsible for retinal damage and the loss of retinal neurons during disease progression. Linked to this is the development of novel neuroprotective drugs that will help preserve the vision of glaucoma patients.
We also have a particular interest in developing a better understanding of the cause of the ocular hypertension that can develop in glaucoma and how new multi-modal drugs may help reduce ocular pressure and protect the retina from further damage.
Professor Ann Logan
Dr Wendy Leadbeater
Dr Zubair Ahmed
Dr Liam Grover - School of Chemical Engineering, College of Engineering and Physical Sciences
Dr Saaeha Rauz - School of Immunity and Infection, College of Medical and Dental Sciences
Wing Commander Robert Scott
Professor Martin Berry
Dr Vasanthy Vigneswara
Dr Felicity de Cogan